Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk

R. J. Barr, A. Stewart, D. J. Torgerson, D. M. Reid

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Randomised control trial of osteoporosis screening in 4,800 women aged 45-54 years was carried out. Screened group observed an increase of 7.9% in hormone replacement therapy (HRT) use (p < 0.001), 15% in other osteoporosis treatments (p < 0.001) and a 25.9% reduction in fracture risk compared with control. Screening for osteoporosis significantly increases treatment use and reduces fracture incidence.

Population screening programmes can identify menopausal women with low bone mineral density (BMD) and elevated risk of future fracture but require to be proven effective by a randomised control trial.

A total of 4,800 women, 45-54 years, were randomised in equal numbers to screening or no screening (control) groups. Following screening, those in the lowest quartile of BMD were advised to consider HRT. Nine years later, the effect of screening on the uptake of treatment and the incidence of fractures were assessed by postal questionnaire. Categorical differences were assessed using chi (2) test. Cox regression was used to assess hazard ratio (HR).

Of the screened and the control groups, 52.4% vs 44.5%, respectively, reported taking HRT (p < 0.001). In addition, 36.6% of the screened vs 21.6% of the control groups reported the use of vitamin D, calcium, alendronate, etidronate or raloxifene (p < 0.001). In a per protocol analysis of verified incident fractures, a 25.9% reduction in risk of fractures (of any site) in the screened group was observed (HR = 0.741, 95% CI = 0.551-0.998 adjusted age, weight and height).

Screening for osteoporosis as assessed by low bone density significantly increases the use of HRT and other treatments for osteoporosis and reduces fracture incidence.

Original languageEnglish
Pages (from-to)561-568
Number of pages8
JournalOsteoporosis International
Volume21
Issue number4
Early online date30 Jun 2009
DOIs
Publication statusPublished - 1 Apr 2010

Fingerprint

Osteoporosis
Hormone Replacement Therapy
Bone Density
Population
Control Groups
Incidence
Etidronic Acid
Alendronate
Fracture Fixation
Population Control
Risk Reduction Behavior
Therapeutics
Vitamin D
Calcium
Weights and Measures

Keywords

  • fracture
  • hormone replacement therapy
  • randomised control trial
  • hormone-replacment therapy
  • postmenopausal osteoperosis
  • nonvertebral fractures
  • vertebral fractures
  • women
  • alendronate
  • prevention
  • diagnosis

Cite this

Population screening for osteoporosis risk : a randomised control trial of medication use and fracture risk. / Barr, R. J.; Stewart, A.; Torgerson, D. J.; Reid, D. M.

In: Osteoporosis International, Vol. 21, No. 4, 01.04.2010, p. 561-568.

Research output: Contribution to journalArticle

Barr, R. J. ; Stewart, A. ; Torgerson, D. J. ; Reid, D. M. / Population screening for osteoporosis risk : a randomised control trial of medication use and fracture risk. In: Osteoporosis International. 2010 ; Vol. 21, No. 4. pp. 561-568.
@article{1da52be5c1974e6e846d716e2abbc410,
title = "Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk",
abstract = "Randomised control trial of osteoporosis screening in 4,800 women aged 45-54 years was carried out. Screened group observed an increase of 7.9{\%} in hormone replacement therapy (HRT) use (p < 0.001), 15{\%} in other osteoporosis treatments (p < 0.001) and a 25.9{\%} reduction in fracture risk compared with control. Screening for osteoporosis significantly increases treatment use and reduces fracture incidence.Population screening programmes can identify menopausal women with low bone mineral density (BMD) and elevated risk of future fracture but require to be proven effective by a randomised control trial.A total of 4,800 women, 45-54 years, were randomised in equal numbers to screening or no screening (control) groups. Following screening, those in the lowest quartile of BMD were advised to consider HRT. Nine years later, the effect of screening on the uptake of treatment and the incidence of fractures were assessed by postal questionnaire. Categorical differences were assessed using chi (2) test. Cox regression was used to assess hazard ratio (HR).Of the screened and the control groups, 52.4{\%} vs 44.5{\%}, respectively, reported taking HRT (p < 0.001). In addition, 36.6{\%} of the screened vs 21.6{\%} of the control groups reported the use of vitamin D, calcium, alendronate, etidronate or raloxifene (p < 0.001). In a per protocol analysis of verified incident fractures, a 25.9{\%} reduction in risk of fractures (of any site) in the screened group was observed (HR = 0.741, 95{\%} CI = 0.551-0.998 adjusted age, weight and height).Screening for osteoporosis as assessed by low bone density significantly increases the use of HRT and other treatments for osteoporosis and reduces fracture incidence.",
keywords = "fracture, hormone replacement therapy, randomised control trial, hormone-replacment therapy, postmenopausal osteoperosis, nonvertebral fractures, vertebral fractures, women, alendronate, prevention, diagnosis",
author = "Barr, {R. J.} and A. Stewart and Torgerson, {D. J.} and Reid, {D. M.}",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s00198-009-1007-x",
language = "English",
volume = "21",
pages = "561--568",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "SPRINGER-VERLAG LONDON LTD",
number = "4",

}

TY - JOUR

T1 - Population screening for osteoporosis risk

T2 - a randomised control trial of medication use and fracture risk

AU - Barr, R. J.

AU - Stewart, A.

AU - Torgerson, D. J.

AU - Reid, D. M.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Randomised control trial of osteoporosis screening in 4,800 women aged 45-54 years was carried out. Screened group observed an increase of 7.9% in hormone replacement therapy (HRT) use (p < 0.001), 15% in other osteoporosis treatments (p < 0.001) and a 25.9% reduction in fracture risk compared with control. Screening for osteoporosis significantly increases treatment use and reduces fracture incidence.Population screening programmes can identify menopausal women with low bone mineral density (BMD) and elevated risk of future fracture but require to be proven effective by a randomised control trial.A total of 4,800 women, 45-54 years, were randomised in equal numbers to screening or no screening (control) groups. Following screening, those in the lowest quartile of BMD were advised to consider HRT. Nine years later, the effect of screening on the uptake of treatment and the incidence of fractures were assessed by postal questionnaire. Categorical differences were assessed using chi (2) test. Cox regression was used to assess hazard ratio (HR).Of the screened and the control groups, 52.4% vs 44.5%, respectively, reported taking HRT (p < 0.001). In addition, 36.6% of the screened vs 21.6% of the control groups reported the use of vitamin D, calcium, alendronate, etidronate or raloxifene (p < 0.001). In a per protocol analysis of verified incident fractures, a 25.9% reduction in risk of fractures (of any site) in the screened group was observed (HR = 0.741, 95% CI = 0.551-0.998 adjusted age, weight and height).Screening for osteoporosis as assessed by low bone density significantly increases the use of HRT and other treatments for osteoporosis and reduces fracture incidence.

AB - Randomised control trial of osteoporosis screening in 4,800 women aged 45-54 years was carried out. Screened group observed an increase of 7.9% in hormone replacement therapy (HRT) use (p < 0.001), 15% in other osteoporosis treatments (p < 0.001) and a 25.9% reduction in fracture risk compared with control. Screening for osteoporosis significantly increases treatment use and reduces fracture incidence.Population screening programmes can identify menopausal women with low bone mineral density (BMD) and elevated risk of future fracture but require to be proven effective by a randomised control trial.A total of 4,800 women, 45-54 years, were randomised in equal numbers to screening or no screening (control) groups. Following screening, those in the lowest quartile of BMD were advised to consider HRT. Nine years later, the effect of screening on the uptake of treatment and the incidence of fractures were assessed by postal questionnaire. Categorical differences were assessed using chi (2) test. Cox regression was used to assess hazard ratio (HR).Of the screened and the control groups, 52.4% vs 44.5%, respectively, reported taking HRT (p < 0.001). In addition, 36.6% of the screened vs 21.6% of the control groups reported the use of vitamin D, calcium, alendronate, etidronate or raloxifene (p < 0.001). In a per protocol analysis of verified incident fractures, a 25.9% reduction in risk of fractures (of any site) in the screened group was observed (HR = 0.741, 95% CI = 0.551-0.998 adjusted age, weight and height).Screening for osteoporosis as assessed by low bone density significantly increases the use of HRT and other treatments for osteoporosis and reduces fracture incidence.

KW - fracture

KW - hormone replacement therapy

KW - randomised control trial

KW - hormone-replacment therapy

KW - postmenopausal osteoperosis

KW - nonvertebral fractures

KW - vertebral fractures

KW - women

KW - alendronate

KW - prevention

KW - diagnosis

U2 - 10.1007/s00198-009-1007-x

DO - 10.1007/s00198-009-1007-x

M3 - Article

C2 - 19565176

VL - 21

SP - 561

EP - 568

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 4

ER -